Abstract

Objective To analyze the outcome and prognosis-related factors of MA (mitoxantrone+cytarabine) regimen for acute myeloid leukemia(AML). Methods 102 untreated AML patients were treated with MA. All patients were divided into two groups according to age, blood white cell count(WBC), FrenchAmerican-British (FAB) morphology, level of lactate dehydrogenase (LDH) and immunophynotype respectively.Analyze the prognosis-related factors. Results The complete remission (CR), partial remission (PR), nonresponse (NR) rate, and remission rate (CR+PR) of all the 102 cases were 63.73 % (65/102), 17.65 % (18/102), 18.62 % (419/102)and 81.38 % (83/102) respectively. The patients younger than 60 years old, WBC＜100×109/L, LDH≤600 U/L, FAB-M2 morphology group had higher CR and remission rate. The CR rate of patients with CD7 positive had statistical difference from that of patients with CD7 negative (P ＜0.05), but the remission rate not. However, the CR and remission rate of patients with CD19 positive had no statistical difference from that of patients with CD19 negative (P ＞0.05). Conclusion These results suggest that use of MA regimen was effective and safe for AML. Age, WBC, FAB morphology, level of LDH and CD7 expression are prognosis-related factors for clinical outcome. Key words: Leukemia, myeloid, acute; Antineoplastic combined chemotherapy protocols; Mitoxantrone

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.